From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
7-[2-amino-2-(4-hydroxyphenyl)-acetyl]amino-8-oxo-3-prop-1-enyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Clinical data
Trade names Cefzil
AHFS/Drugs.com monograph
MedlinePlus a698022
  • US: B (No risk in non-human studies)
Pharmacokinetic data
Bioavailability 95%
Protein binding 36%
Half-life 1.3 hours
92665-29-7 YesY
PubChem CID 9887643
DrugBank DB01150 YesY
ChemSpider 8063315 YesY
UNII 1M698F4H4E YesY
KEGG D07651 YesY
Chemical data
Formula C18H19N3O5S
389.427 g/mol
 N (what is this?)  (verify)

Cefprozil, sometimes spelled cefproxil and marketed under the trade name Cefzil, is a second-generation cephalosporin type antibiotic. In Europe it is marketed using the trade names Procef and Cronocef.[citation needed] It can be used to treat bronchitis, ear infections, skin infections, and other bacterial infections.[citation needed] It comes as a tablet and as a liquid suspension.

Although there is a widely quoted cross-allergy risk of 10% between cephalosporins and penicillin, an article in the Journal of Family Practice[1] has shown no increased risk for cross-allergy for cefprozil and several other second-generation or later cephalosporins.

Spectrum of bacterial susceptibility and resistance[edit]

Currently bacteria like Enterobacter aerogenes, Morganella morganii and Pseudomonas aeruginosa are resistant to Cefprozil, while Salmonella Agona and Streptococci are susceptible to Cefprozil. Some of the bacteria like Brucella abortus, Moraxella catarrhalis and Streptococcus pneumonia have developed resistance towards Cefprozil in varying degrees. For detailed minimum inhibition concentration information, please refer to Cefprozil Susceptibility and Resistance Data sheet.[2]


External links[edit]